Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer

ConclusionOur results support the feasibility of combining propranolol (up to 80  mg ER) with neoadjuvant taxane/anthracycline-based chemotherapy.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research